Imunon, Inc. Available-for-sale Securities, Gross Realized Losses
Imunon, Inc. (IMNN) reported Available-for-sale Securities, Gross Realized Losses of $3.08 thousand for the 3-month period ending 2014-06-30, per its 10-Q filed 2014-08-07.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses · last filed 2014-08-07
- Imunon, Inc. available-for-sale securities, gross realized losses for the quarter ending 2014-06-30 was $3.08K, a 97.75% decline year-over-year.
- Imunon, Inc. available-for-sale securities, gross realized losses for the quarter ending 2014-03-31 was $20.61K, a 61.65% decline year-over-year.
- Imunon, Inc. available-for-sale securities, gross realized losses for the quarter ending 2013-06-30 was $136.94K.
- Imunon, Inc. available-for-sale securities, gross realized losses for the quarter ending 2013-03-31 was $53.74K.
| Period end | Available-for-sale Securities, Gross Realized Losses 3 month | Available-for-sale Securities, Gross Realized Losses 6 month |
|---|---|---|
| 2014-06-30 | $3.08K 10-Q · filed 2014-08-07 | $23.69K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $20.61K 10-Q · filed 2014-05-08 | |
| 2013-06-30 | $136.94K 10-Q · filed 2014-08-07 | $190.68K 10-Q · filed 2014-08-07 |
| 2013-03-31 | $53.74K 10-Q · filed 2014-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |